Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus SULFANILAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus SULFANILAMIDE.
MICROSUL vs SULFANILAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folic acid synthesis.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
2-4 g orally initially, then 2-4 g every 4-6 hours, not to exceed 12 g/day; intravenous: 4-8 g/day in divided doses every 6-8 hours.
None Documented
None Documented
Clinical Note
moderateSulfanilamide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide."
Clinical Note
moderateSulfanilamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin."
Clinical Note
moderateSulfanilamide + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine."
Clinical Note
moderateTerminal elimination half-life: 24-36 hours; prolonged in renal impairment
Terminal elimination half-life: 7-12 hours; prolonged in renal impairment (up to 24-48 hours).
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Primarily renal via glomerular filtration and tubular secretion; ~50-70% excreted unchanged in urine; biliary/fecal excretion minimal (<5%).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
Sulfanilamide + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfanilamide."